Genetics

This post covers Zahoor and colleagues' 2022 PNAS study, which takes serum metabolomics in treatment-naive relapsing-remitting MS patients through to a tested therapeutic target. It reports the 60 altered metabolites and the four enriched pathways, noting that only glycerophospholipid metabolism survived FDR correction; the convergence argument identifying glycolysis as the shared upstream feeder; the finding that patient cells are more glycolytic without any change in glycolytic gene expression; efficacy of 2-deoxy-D-glucose across four mouse models by two routes; the adoptive transfer experiment showing monocytes carry the protection; and the limits of the compound and the human cohort.